vs
EVgo Inc.（EVGO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是EVgo Inc.的1.7倍（$207.3M vs $118.5M），EVgo Inc.净利率更高（-4.1% vs -62.0%，领先57.9%），EVgo Inc.同比增速更快（75.5% vs 25.9%），EVgo Inc.自由现金流更多（$-38.1M vs $-100.8M），过去两年EVgo Inc.的营收复合增速更高（46.6% vs 38.0%）
EVgo Inc.是美国知名的电动汽车快充网络运营商，截至2023年8月，公司已布局超过950个充电站点，覆盖美国35个州，旗下充电桩兼容全球各大主流车企的电动汽车。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EVGO vs RARE — 直观对比
营收规模更大
RARE
是对方的1.7倍
$118.5M
营收增速更快
EVGO
高出49.6%
25.9%
净利率更高
EVGO
高出57.9%
-62.0%
自由现金流更多
EVGO
多$62.7M
$-100.8M
两年增速更快
EVGO
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.5M | $207.3M |
| 净利润 | $-4.8M | $-128.6M |
| 毛利率 | 38.0% | — |
| 营业利润率 | -10.4% | -54.7% |
| 净利率 | -4.1% | -62.0% |
| 营收同比 | 75.5% | 25.9% |
| 净利润同比 | 61.1% | 3.5% |
| 每股收益（稀释后） | $-0.03 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVGORARE
| Q4 25 | $118.5M | $207.3M | ||
| Q3 25 | $92.3M | $159.9M | ||
| Q2 25 | $98.0M | $166.5M | ||
| Q1 25 | $75.3M | $139.3M | ||
| Q4 24 | $67.5M | $164.6M | ||
| Q3 24 | $67.5M | $139.5M | ||
| Q2 24 | $66.6M | $147.0M | ||
| Q1 24 | $55.2M | $108.8M |
净利润EVGORARE
| Q4 25 | $-4.8M | $-128.6M | ||
| Q3 25 | $-12.4M | $-180.4M | ||
| Q2 25 | $-13.0M | $-115.0M | ||
| Q1 25 | $-11.4M | $-151.1M | ||
| Q4 24 | $-12.4M | $-133.2M | ||
| Q3 24 | $-11.7M | $-133.5M | ||
| Q2 24 | $-10.4M | $-131.6M | ||
| Q1 24 | $-9.8M | $-170.7M |
毛利率EVGORARE
| Q4 25 | 38.0% | — | ||
| Q3 25 | 13.6% | — | ||
| Q2 25 | 14.2% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 9.4% | — | ||
| Q2 24 | 9.6% | — | ||
| Q1 24 | 12.4% | — |
营业利润率EVGORARE
| Q4 25 | -10.4% | -54.7% | ||
| Q3 25 | -36.9% | -106.9% | ||
| Q2 25 | -31.4% | -64.8% | ||
| Q1 25 | -44.4% | -102.6% | ||
| Q4 24 | -51.9% | -74.3% | ||
| Q3 24 | -47.1% | -94.6% | ||
| Q2 24 | -48.6% | -79.1% | ||
| Q1 24 | -58.7% | -151.9% |
净利率EVGORARE
| Q4 25 | -4.1% | -62.0% | ||
| Q3 25 | -13.4% | -112.8% | ||
| Q2 25 | -13.3% | -69.0% | ||
| Q1 25 | -15.1% | -108.5% | ||
| Q4 24 | -18.4% | -80.9% | ||
| Q3 24 | -17.3% | -95.7% | ||
| Q2 24 | -15.6% | -89.5% | ||
| Q1 24 | -17.8% | -156.8% |
每股收益（稀释后）EVGORARE
| Q4 25 | $-0.03 | $-1.28 | ||
| Q3 25 | $-0.09 | $-1.81 | ||
| Q2 25 | $-0.10 | $-1.17 | ||
| Q1 25 | $-0.09 | $-1.57 | ||
| Q4 24 | $-0.11 | $-1.34 | ||
| Q3 24 | $-0.11 | $-1.40 | ||
| Q2 24 | $-0.10 | $-1.52 | ||
| Q1 24 | $-0.09 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.0M | $421.0M |
| 总债务越低越好 | $206.5M | — |
| 股东权益账面价值 | $-116.9M | $-80.0M |
| 总资产 | $964.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EVGORARE
| Q4 25 | $151.0M | $421.0M | ||
| Q3 25 | $181.3M | $202.5M | ||
| Q2 25 | $154.5M | $176.3M | ||
| Q1 25 | $150.0M | $127.1M | ||
| Q4 24 | $117.3M | $174.0M | ||
| Q3 24 | $141.9M | $150.6M | ||
| Q2 24 | $162.3M | $480.7M | ||
| Q1 24 | $175.1M | $112.3M |
总债务EVGORARE
| Q4 25 | $206.5M | — | ||
| Q3 25 | $157.3M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EVGORARE
| Q4 25 | $-116.9M | $-80.0M | ||
| Q3 25 | $-428.1M | $9.2M | ||
| Q2 25 | $-230.1M | $151.3M | ||
| Q1 25 | $-36.8M | $144.2M | ||
| Q4 24 | $-256.1M | $255.0M | ||
| Q3 24 | $-344.8M | $346.8M | ||
| Q2 24 | $13.6M | $432.4M | ||
| Q1 24 | $25.7M | $140.3M |
总资产EVGORARE
| Q4 25 | $964.8M | $1.5B | ||
| Q3 25 | $931.8M | $1.2B | ||
| Q2 25 | $864.7M | $1.3B | ||
| Q1 25 | $856.0M | $1.3B | ||
| Q4 24 | $803.8M | $1.5B | ||
| Q3 24 | $791.7M | $1.5B | ||
| Q2 24 | $785.3M | $1.6B | ||
| Q1 24 | $787.5M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-38.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | -32.2% | -48.6% |
| 资本支出强度资本支出/营收 | 41.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-124.4M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流EVGORARE
| Q4 25 | $11.3M | $-99.8M | ||
| Q3 25 | $-22.8M | $-91.4M | ||
| Q2 25 | $14.1M | $-108.3M | ||
| Q1 25 | $-10.2M | $-166.5M | ||
| Q4 24 | $-12.8M | $-79.3M | ||
| Q3 24 | $12.1M | $-67.0M | ||
| Q2 24 | $7.6M | $-77.0M | ||
| Q1 24 | $-14.1M | $-190.7M |
自由现金流EVGORARE
| Q4 25 | $-38.1M | $-100.8M | ||
| Q3 25 | $-49.0M | $-92.7M | ||
| Q2 25 | $-12.1M | $-110.7M | ||
| Q1 25 | $-25.2M | $-167.8M | ||
| Q4 24 | $-36.5M | $-79.5M | ||
| Q3 24 | $-13.7M | $-68.6M | ||
| Q2 24 | $-16.6M | $-79.0M | ||
| Q1 24 | $-35.2M | $-193.9M |
自由现金流率EVGORARE
| Q4 25 | -32.2% | -48.6% | ||
| Q3 25 | -53.1% | -58.0% | ||
| Q2 25 | -12.4% | -66.5% | ||
| Q1 25 | -33.5% | -120.5% | ||
| Q4 24 | -54.1% | -48.3% | ||
| Q3 24 | -20.3% | -49.2% | ||
| Q2 24 | -25.0% | -53.7% | ||
| Q1 24 | -63.7% | -178.2% |
资本支出强度EVGORARE
| Q4 25 | 41.7% | 0.5% | ||
| Q3 25 | 28.3% | 0.8% | ||
| Q2 25 | 26.7% | 1.5% | ||
| Q1 25 | 19.9% | 1.0% | ||
| Q4 24 | 35.1% | 0.1% | ||
| Q3 24 | 38.3% | 1.2% | ||
| Q2 24 | 36.3% | 1.4% | ||
| Q1 24 | 38.2% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVGO
| Charging Network Revenue | $63.6M | 54% |
| Charging Revenue Retail | $35.8M | 30% |
| Charging Revenue Commercial | $9.3M | 8% |
| Charging Revenue Oem | $6.5M | 6% |
| Regulatory Credit Sales | $2.2M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
